Kaiser Permanente contributed to a round that pushed the total raised by the Stanford-aligned cellular cancer therapy developer to $300m.
Orca Bio, a US-based cell therapy developer partly based on Stanford University research, secured $192m on Wednesday in a series D round featuring healthcare provider Kaiser Permanente’s Group Trust as well as its Kaiser Foundation Hospitals subsidiary.
Venture capital firm Lightspeed Venture Partners co-led the round with an unnamed additional investor, while 8VC, Data Collective’s DCVC Bio unit, ND Capital, the Abu Dhabi-owned Mubadala Investment Company and Illinois Municipal Retirement Fund also took part.
Founded in 2016, Orca…